ARPA-H Just Bet $144 Million That Aging Is a Treatable Condition — Here Are the Seven Teams Racing to Prove It

For decades, the federal research establishment treated aging as an inevitability — the backdrop against which specific diseases appeared, not a condition worth targeting directly. Alzheimer's got its own institute. Cancer got a moonshot. But the biological process that makes all of them more likely with every passing year? That was just life.

ARPA-H is now betting $144 million that this framework is wrong. The agency's PROactive Solutions for Prolonging Resilience (PROSPR) program, announced in February, selected seven research teams to develop therapeutics and assessment tools aimed at extending healthspan — the years people live in good health before chronic disease takes hold. It is the largest coordinated federal investment in treating aging as a biological target, and the specific teams chosen reveal a strategy far more sophisticated than simply throwing money at longevity startups.

Seven Teams, Four Distinct Scientific Bets

PROSPR's portfolio is not a scattershot approach. The seven awardees represent four fundamentally different hypotheses about what drives biological aging and how to intervene.

The Repurposing Play: UT Health San Antonio ($38 million)

The largest single award went to the Sam and Ann Barshop Institute for Longevity and Aging Studies, led by Elena Volpi, MD, PhD. The VITAL-H trial will test three FDA-approved medications — rapamycin, dapagliflozin (an SGLT2 inhibitor), and semaglutide — in healthy adults aged 60-65. All three drugs are already prescribed for other conditions, have well-characterized safety profiles at low doses, and target distinct pathways implicated in aging.

This is strategically brilliant. By repurposing approved drugs, Volpi's team sidesteps years of preclinical development and Phase I safety testing. If any of these interventions demonstrably slows functional decline in healthy older adults, the path to clinical adoption is measured in years, not decades. The trial recruits from South Texas, a region whose demographics mirror projected U.S. population composition — a deliberate choice that strengthens the generalizability of whatever results emerge.

The Retrotransposon Hypothesis: University of Rochester ($22 million)

Vera Gorbunova's team at Rochester is pursuing one of the more audacious ideas in geroscience: that ancient viral DNA embedded in our genome is slowly killing us. Retrotransposons — genetic sequences that can copy and paste themselves throughout chromosomes — become increasingly active with age. When they do, the immune system treats the activity as a viral infection, triggering chronic inflammation that accelerates neurodegeneration, cancer, and metabolic disease.

The intervention is censavudine (TPN-101), an HIV drug that inhibits reverse transcriptase, the enzyme retrotransposons need to replicate. The logic is elegant: if you can suppress retrotransposon activity with a drug that already has established human safety data, you might be able to reduce the chronic, DNA-triggered inflammation that drives much of age-related decline.

Rochester's clinical trial will enroll 200 healthy adults aged 60-65 in a randomized, placebo-controlled study lasting 48 weeks. Collaborating institutions include Brown University, where John Sedivy directs the Center on the Biology of Aging, along with UConn Health and the University of Texas Medical Branch. As Sedivy put it, "the goal is not to treat diseases, but to treat aging itself — the normal, healthy process of human aging."

The Next-Generation mTOR Approach: Cambrian BioPharma ($30.8 million)

Rapamycin is the closest thing geroscience has to a consensus drug candidate — it extends lifespan in multiple animal models and modulates the mTOR pathway central to cellular growth and metabolism. But rapamycin itself has immunosuppressive side effects that make long-term use in healthy people problematic.

Cambrian BioPharma received $30.8 million to develop an oral rapamycin analog that selectively targets mTORC1 — the arm of the mTOR pathway most associated with aging — while minimizing effects on mTORC2, which is linked to immune suppression. This selectivity, if achievable, would resolve the central pharmacological challenge that has kept rapamycin from becoming a viable longevity therapeutic.

The GPER Pathway: Linnaeus Therapeutics ($22 million)

Linnaeus is testing LNS8801, a compound targeting the G protein-coupled estrogen receptor (GPER). The company built its initial dataset in oncology, treating over 100 cancer patients and observing what it described as healthspan benefits beyond tumor response. PROSPR funding will let them explore whether those benefits extend to aging in the absence of disease.

Platform and Biomarker Development: Stanford and Columbia

Not every PROSPR team is testing drugs. Stanford's contribution focuses on harmonizing health datasets and developing a healthspan score — a composite metric that could standardize how researchers measure whether someone is aging well or poorly. The team is also building in-home digital assessment tools that could enable decentralized trial designs, removing the geographic barriers that typically limit clinical research enrollment.

Columbia University's Mailman School of Public Health is tackling the biomarker problem from a different angle, analyzing data across multiple PROSPR trials to identify which molecular markers respond earliest and most reliably to intervention. This cross-trial analysis could determine which biomarkers become standard endpoints in future geroscience research.

Apollo Alpha rounds out the portfolio with an oral compound targeting energy homeostasis and inflammation — though the company has disclosed fewer details about its specific mechanism than other awardees.

Why PROSPR's Trial Design Matters as Much as Its Drug Choices

The biggest obstacle to aging research has never been a shortage of promising compounds. It has been the impossibility of running conventional clinical trials. If your endpoint is "does this person develop fewer age-related diseases over 20 years," you need a trial that runs for two decades. No funder will pay for that. No regulator will wait for it.

PROSPR's answer is to redefine the endpoint. Instead of measuring disease incidence over decades, teams will measure "intrinsic capacity" — a composite of cognition, mobility, psychological function, vitality, and sensory ability — over one to three years. The hypothesis is that early changes in intrinsic capacity predict long-term health trajectories, so demonstrating improvement on these measures within a compressed timeframe could serve as a surrogate for lasting benefit.

This is not without scientific risk. Surrogate endpoints have a mixed track record in medicine — drugs that improve biomarkers do not always improve outcomes. But PROSPR's design includes safeguards: Stanford's healthspan scoring system and Columbia's cross-trial biomarker analysis are specifically tasked with validating which short-term measures actually predict long-term health. If those validation efforts succeed, they will have built the measurement infrastructure that makes all future aging trials feasible.

The decentralized trial design is equally significant. Traditional clinical trials require participants to travel to academic medical centers for every assessment — a model that systematically excludes rural populations, working-class communities, and anyone without the time and resources to spend days at a university hospital. PROSPR teams are deploying wearable technology and in-home monitoring that could make aging research as geographically inclusive as the population it aims to serve.

What This Means for the Geroscience Field

ARPA-H's structure as a contracts agency rather than a grants agency is doing real work here. PROSPR awards are contracts contingent on meeting aggressive research milestones, not open-ended grants with annual progress reports. Teams that fall behind lose funding. This creates urgency that the traditional NIH grants process — with its multi-year review cycles and generous no-cost extensions — does not.

The broader signal is harder to quantify but may matter more. Federal agencies have historically been reluctant to fund research premised on treating aging as a medical condition. The NIA funds aging-related disease research; NIH funds disease-specific interventions. But the idea that aging itself is a modifiable biological process — that you could intervene on the upstream cause rather than treating downstream diseases one at a time — has lived mostly in private-sector longevity companies and a handful of academic labs.

PROSPR brings that idea into the federal research mainstream. When ARPA-H commits $144 million and seven teams to the proposition that biological aging can be slowed with drugs, it legitimizes a research agenda that philanthropic funders and venture capitalists have been backing for years. It also creates a pipeline: if PROSPR trials produce positive results, the logical next step is larger NIH-funded confirmatory studies and, eventually, FDA consideration of aging as an indication.

Who Should Be Watching This

If you work in geroscience, geriatric medicine, biomarker development, clinical trial design, or health technology assessment, PROSPR is setting the terms for the next decade of aging research. The measurement tools Stanford develops, the biomarkers Columbia validates, and the clinical results from UT San Antonio, Rochester, Cambrian, and Linnaeus will collectively determine whether "treat aging" becomes a real category of medicine or remains an aspiration.

For researchers and institutions looking to position themselves in this emerging field, the time to build capacity is now — not after the first PROSPR results are published. ARPA-H has signaled that it views aging therapeutics as a priority area, and follow-on funding is likely if early milestones are met.

The drug candidates are identified. The trial designs are novel. The funding is committed. What remains is whether the science delivers — and whether the federal research ecosystem is ready to act on the results if it does. Platforms like Granted can help researchers track these emerging opportunities and build proposals that match where the field is heading, not where it has been.